Skip to Content

Dronabinol Dosage

Applies to the following strength(s): 2.5 mg ; 5 mg ; 10 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced

-Initial Dose: 5 mg/m2 orally 1 to 3 hours prior to chemotherapy administration, then every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses a day.

-Maintenance Dose: May escalate dose by 2.5 mg/m2 increments during a chemotherapy cycle or at subsequent cycles if the initial dose is ineffective and there are no significant side effects.

-Maximum Dose: 15 mg/m2 per dose

Comments:
-Most patients respond to 5 mg given 3 or 4 times daily.
-Clinical trial data indicate escalating the dose above 7 mg/m2 increased the frequency of adverse effects with no additional antiemetic benefit.

Use: Treatment for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Usual Adult Dose for Anorexia

-Initial Dose: 2.5 mg orally twice a day before lunch and dinner; Reduce dose to 2.5 mg orally once a day in the evening or at bedtime for patients unable to tolerate 5 mg/day.

-Maintenance dose: May increase dose to 7.5 mg/day or 10 mg/day orally (2.5 mg before lunch and 5 mg before dinner OR 5 mg before lunch and 5 mg before dinner) when adverse effects are absent/minimal or when further therapeutic effect is desired.

-Maximum dose: Gradual increase to 20 mg/day (10 mg orally twice a day before lunch and dinner)

Comments:
-The majority of patients in clinical trials were treated with 5 mg/day, although the dosages ranged from 2.5 to 20 mg/day.
-If CNS symptoms (e.g., feeling high, dizziness, confusion, somnolence) occur, they usually resolve in 1 to 3 days with continued dosage.
-Early morning administration has been associated with an increased frequency of adverse reactions as compared to dosing later in the day.

Use: Appetite stimulant for anorexia associated with weight loss in AIDS patients.

Usual Pediatric Dose for Nausea/Vomiting - Chemotherapy Induced

-Initial Dose: 5 mg/m2 orally 1 to 3 hours prior to chemotherapy administration, then every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses a day.

-Maintenance Dose: May escalate dose by 2.5 mg/m2 increments during a chemotherapy cycle or at subsequent cycles if the initial dose is ineffective and there are no significant side effects.

-Maximum Dose: 15 mg/m2 per dose

Comments:
-This drug should be used with caution in children because of its psychoactive effects.
-Most patients respond to 5 mg given 3 or 4 times daily.
-Clinical trial data indicate escalating the dose above 7 mg/m2 increased the frequency of adverse effects with no additional antiemetic benefit.

Use: Treatment for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Severe or Persistent CNS Symptoms (when treating anorexia in AIDS patients):
-2.5 mg orally once a day before dinner
-Dose should be given in the evening or at bedtime if symptoms continue to be a problem.

Precautions

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule III

Dialysis

Data not available

Other Comments

Administration Advice:
-Caution is recommended in dose escalation due to the significant increase of disturbing psychiatric symptoms at the maximum dose.
-Coadministration with phenothiazines (e.g., prochlorperazine) may result in improved efficacy, as compared to either drug alone, without additional toxicity.
-Dose individualization is recommended to achieve maximum treatment benefit.
-Therapy should be initiated at the lowest recommended dose and titrated to clinical response.

Storage Requirements:
-This drug should be packaged in a well-closed container, kept refrigerated at 2 to 8 degrees Celsius (36 to 46 Fahrenheit), and protected from freezing.

General:
-This drug demonstrates reversible, dose-related effects on appetite, mood, cognition, memory, and perception; these phenomena increase in frequency with higher dosages and are subject to great interpatient variability.
-Tachyphylaxis and tolerance develop to some of the pharmacologic effects of this drug and other cannabinoids with chronic use; however, they do not appear to develop to the appetite stimulant effect of this drug.
-The estimated lethal human dose is 30 mg/kg (IV).
-Overdosage: Gut decontamination is recommended for recent serious oral ingestion; the manufacturer product information should be consulted for overdose management.

Patient Advice:
-This drug may cause side effects such as dizziness and drowsiness that can affect your ability to perform certain activities; avoid driving and tasks such as operating machinery until you know that you can perform these activities safely during treatment.
-Do not drink alcohol while taking this drug.

Hide